Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) — Free Cash Flow Generation Index
Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has a Free Cash Flow Generation Index of -0.27x as of September 2025. Free cash flow of CN¥-2.50 Million represents 0% of operating cash flow (CN¥9.12 Million). Explore 300942 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Shenzhen Bioeasy Biotechnology Co. Ltd. Free Cash Flow Generation Index (2016–2025)
Historical FCF Generation Index trend for Shenzhen Bioeasy Biotechnology Co. Ltd. across 9 annual periods. For the full cash flow conversion analysis, see how efficiently does Shenzhen Bioeasy Biotechnology Co. Ltd. generate cash.
Annual Free Cash Flow Generation for Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
Year-by-year Free Cash Flow Generation Index for Shenzhen Bioeasy Biotechnology Co. Ltd.. Check Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.31x | CN¥20.97 Million | CN¥66.87 Million | CN¥45.90 Million | ▲ +107.7% |
| 2024 | -4.08x | CN¥-139.85 Million | CN¥34.26 Million | CN¥174.10 Million | ▼ -2463.4% |
| 2022 | -0.16x | CN¥-24.29 Million | CN¥152.55 Million | CN¥176.85 Million | ▼ -123.1% |
| 2021 | 0.69x | CN¥175.92 Million | CN¥255.42 Million | CN¥79.51 Million | ▲ +330.7% |
| 2020 | -0.30x | CN¥-19.04 Million | CN¥63.79 Million | CN¥82.84 Million | ▼ -149.0% |
| 2019 | 0.61x | CN¥40.95 Million | CN¥67.24 Million | CN¥26.29 Million | ▼ -25.6% |
| 2018 | 0.82x | CN¥47.40 Million | CN¥57.93 Million | CN¥10.53 Million | ▲ +51.1% |
| 2017 | 0.54x | CN¥12.79 Million | CN¥23.60 Million | CN¥10.82 Million | ▼ -27.9% |
| 2016 | 0.75x | CN¥27.29 Million | CN¥36.31 Million | CN¥9.03 Million | — |